文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

分娩后单次低剂量艾司氯胺酮对有产前抑郁症状产妇的疗效:随机临床试验

Efficacy of a single low dose of esketamine after childbirth for mothers with symptoms of prenatal depression: randomised clinical trial.
PubMed 文献 · BMJ · 2024-04-10

在中国5家三级医院开展的随机双盲安慰剂对照试验纳入364名产前抑郁产妇,分娩后单次静脉输注0.2 mg/kg艾司氯胺酮或安慰剂。产后42天艾司氯胺酮组重性抑郁发作比例为6.7%(12/180),安慰剂组为25.4%(46/181),相对危险度为0.26(95%CI 0.14至0.48;P<0.001)。艾司氯胺酮组神经精神不良事件总体发生率较高(45.1%对22.0%),但症状持续不到一天且无需药物治疗。

要点

  • 产前抑郁产妇分娩后单次低剂量艾司氯胺酮可降低产后42天重性抑郁发作风险。
  • 艾司氯胺酮组神经精神不良事件发生率45.1%,高于安慰剂组22.0%,症状短暂且无需药物处理。
  • 产后7天和42天爱丁堡产后抑郁量表评分及42天汉密尔顿抑郁量表评分艾司氯胺酮组均较低。

核心结论

  • 对有产前抑郁的产妇,分娩后单次低剂量艾司氯胺酮使产后42天重性抑郁发作减少约四分之三。
  • 神经精神症状更常见但为短暂性,且无需药物干预。

研究设计与样本

  • 随机、双盲、安慰剂对照、两平行组试验,在中国5家三级医院进行,时间为2020年6月19日至2022年8月3日。
  • 共纳入364名年龄≥18岁、爱丁堡产后抑郁量表评分≥10(范围0-30,评分越高抑郁越重)且住院分娩的产妇,按1:1随机分配。
  • 干预为断脐后40分钟内静脉输注0.2 mg/kg艾司氯胺酮或安慰剂。

主要发现

  • 产后42天重性抑郁发作在艾司氯胺酮组为6.7%(12/180),安慰剂组为25.4%(46/181),相对危险度0.26(95%CI 0.14至0.48;P<0.001)。
  • 艾司氯胺酮组产后7天爱丁堡产后抑郁量表评分中位数差异为-3(95%CI -4至-2;P<0.001),产后42天为-3(95%CI -4至-2;P<0.001)。
  • 艾司氯胺酮组产后42天汉密尔顿抑郁量表17项评分差异为-4(95%CI -6至-3;P<0.001)。
  • 神经精神不良事件总体发生率艾司氯胺酮组为45.1%(82/182),安慰剂组为22.0%(40/182),P<0.001;症状持续不到一天,无一人需要药物治疗。

关键数值与推荐

  • 产前抑郁定义为爱丁堡产后抑郁量表评分≥10(范围0-30,评分越高抑郁越重)。
  • 主要结局为产后42天采用简易国际神经精神访谈诊断的重性抑郁发作患病率。
  • 次要结局包括产后7天和42天爱丁堡产后抑郁量表评分及产后42天汉密尔顿抑郁量表17项评分(范围0-52,评分越高抑郁越重)。
  • 不良事件监测至分娩后24小时。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether a single low dose of esketamine administered after childbirth reduces postpartum depression in mothers with prenatal depression. DESIGN: Randomised, double blind, placebo controlled trial with two parallel arms. SETTING: Five tertiary care hospitals in China, 19 June 2020 to 3 August 2022. PARTICIPANTS: 364 mothers aged ≥18 years who had at least mild prenatal depression as indicated by Edinburgh postnatal depression scale scores of ≥10 (range 0-30, with higher scores indicating worse depression) and who were admitted to hospital for delivery. INTERVENTIONS: Participants were randomly assigned 1:1 to receive either 0.2 mg/kg esketamine or placebo infused intravenously over 40 minutes after childbirth once the umbilical cord had been clamped. MAIN OUTCOME MEASURES: The primary outcome was prevalence of a major depressive episode at 42 days post partum, diagnosed using the mini-international neuropsychiatric interview. Secondary outcomes included the Edinburgh postnatal depression scale score at seven and 42 days post partum and the 17 item Hamilton depression rating scale score at 42 days post partum (range 0-52, with higher scores indicating worse depression). Adverse events were monitored until 24 hours after childbirth. RESULTS: A total of 364 mothers (mean age 31.8 (standard deviation 4.1) years) were enrolled and randomised. At 42 days post partum, a major depressive episode was observed in 6.7% (12/180) of participants in the esketamine group compared with 25.4% (46/181) in the placebo group (relative risk 0.26, 95% confidence interval (CI) 0.14 to 0.48; P<0.001). Edinburgh postnatal depression scale scores were lower in the esketamine group at seven days (median difference -3, 95% CI -4 to -2; P<0.001) and 42 days (-3, -4 to -2; P<0.001). Hamilton depression rating scale scores at 42 days post partum were also lower in the esketamine group (-4, -6 to -3; P<0.001). The overall incidence of neuropsychiatric adverse events was higher in the esketamine group (45.1% (82/182) v 22.0% (40/182); P<0.001); however, symptoms lasted less than a day and none required drug treatment. CONCLUSIONS: For mothers with prenatal depression, a single low dose of esketamine after childbirth decreases major depressive episodes at 42 days post partum by about three quarters. Neuropsychiatric symptoms were more frequent but transient and did not require drug intervention. TRIAL REGISTRATION: ClinicalTrials.gov NCT04414943.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Wang S, Deng CM, Zeng Y, et al. Efficacy of a single low dose of esketamine after childbirth for mothers with symptoms of prenatal depression: randomised clinical trial. BMJ. 2024. PMID: 38808490. doi:10.1136/bmj-2023-078218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。